Why the study?
Does ultralow-dose aspirin impair platelet aggregation and alter P-selectin expression in clinically normal dogs?
Population
18 clinically normal dogs
Comparison
Ultralow-dose aspirin vs Baseline (before ULDAsp administration)
Design
Preclinical
Follow-up
24 hours after 2-day administration
Authors
Loading...
Ultralow-dose aspirin effects in healthy dogs require validation in disease models; leaves open clinical antithrombotic utility in veterinary practice.
Does ultralow-dose aspirin impair platelet aggregation and alter P-selectin expression in clinically normal dogs?
Ultralow-dose aspirin impairs platelet aggregation in most clinically normal dogs but does not influence CD62P platelet membrane expression.
Sharpe et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: